CClinicalTrials.gg
RecruitingNCT06376565Updated Nov 14, 2025

Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps

An interventional study of Best Practice and Communication Intervention in Colorectal Carcinoma, sponsored by Jonsson Comprehensive Cancer Center. Recruiting at 1 site in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-14.

Sponsored by Jonsson Comprehensive Cancer Center · Not applicable, Interventional, and Screening

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Nov 2023, registered Apr 2024).
  • Started Nov 2023; still recruiting 2 years 10 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
1,680
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

This clinical trial tests a multilevel intervention at the clinic, provider and patient levels, to improve colonoscopy surveillance in patients with high risk colon polyps. Colorectal cancer (CRC) is a common and deadly disease that is largely preventable through the detection and removal of colorectal polyps. One million Americans are diagnosed with high risk polyps of the colon or rectum annually and are at increased risk for CRC; however, uptake of recommended repeat colonoscopy in 3 years to reduce CRC risk is low in this group. This multilevel intervention may work to improve timely colonoscopy screening for patients with high risk colon polyps.

Read the detailed description

PRIMARY OBJECTIVE:

I. To increase completion of surveillance colonoscopy within 3.5 years of high risk neoplasia (HRN) diagnosis.

OUTLINE:

AIM 1: Participants complete an interview over 20-30 minutes.

AIM 2: Primary care clinics are randomized to 1 of 2 arms.

ARM I: Clinics have the automatic addition of HRN to the medical problem list and indication of surveillance interval is added to the health maintenance portion of the electronic health records. Clinics also call patients to schedule their colonoscopy. Providers receive reminders and pending orders for the colonoscopy in the electronic health record. Patients receive a reminder 6 months in advance via their patient portal and mail to schedule a colonoscopy, and also receive a phone call from the patient communication center.

ARM II: Patients receive care according to the clinics' usual care practices.

02

Conditions studied

  • Colorectal Carcinoma
03

In context

Colorectal Neoplasms

5,599 studies on the registry are indexed under Colorectal Neoplasms; 1,459 are open to participants now.

This study's planned enrollment of 1,680 is above the median of 77 across 4,123 interventional studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

Jonsson Comprehensive Cancer Center is the lead sponsor of 396 studies on the registry; 67 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 2 (5%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • AIM 1 PATIENTS: Patients between age 45 and 75 with a HRN diagnosis in the past 5 years
  • AIM 1 PATIENTS: 12 patients who did and 12 patients who did not have surveillance colonoscopy
  • AIM 1 PROVIDERS: Primary care providers (PCPs) and gastroenterologists (GIs)
  • AIM 1 ADMINISTRATORS: Administrators who are involved in care processes related to CRC screening, HRN surveillance, and/or colonoscopy scheduling
  • AIM 2: Patients age 45 to 75 diagnosed with a HRN during the pre-specified two-year HRN diagnosis period

Exclusion criteria

Exclusion Criteria:

  • AIM 2: Individuals with a personal history of colorectal carcinoma (CRC), inflammatory bowel disease (Crohn's, ulcerative colitis), or polyposis syndrome
  • AIM 2: HRN cases not confirmed by chart review (human-in-the-loop)
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,680 participants (estimated)

Study arms

  • Experimental
    Arm I(Multilevel intervention)

    Aim 1: Participants complete an interview over 20-30 minutes. Aim 2: Clinics have the automatic addition of HRN to the medical problem list and indication of surveillance interval is added to the health maintenance portion of the electronic health records (EHR). Clinics also call patients to schedule their colonoscopy. Providers receive reminders and pending orders for the colonoscopy in the electronic health record. Patients receive a reminder 6 months in advance via their patient portal and mail to schedule a colonoscopy, and also receive a phone call from the patient communication center.

    Other: Communication Intervention · Other: Interview

  • Active comparator
    Arm II (Standard follow up)

    Patients receive care according to the clinics' usual care practices.

    Other: Best Practice · Other: Interview

Interventions

  • OtherBest Practice

    Receive standard care

    Also known as: standard of care, standard therapy

  • OtherCommunication Intervention

    Complete clinic EHR interventions

  • OtherCommunication Intervention

    Receive scheduling reminders

  • OtherCommunication Intervention

    Receive reminders and pending EHR orders

  • OtherInterview

    Complete interview

  • OtherInterview

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Stakeholder perspectives on the multilevel intervention (Aim 1)

    The Investigators will conduct 1-on-1 in-depth interviews with patients, advocates, providers, and administrators. these interviews will provide data in closer proximity to intervention implementation to optimize composition, timing, and acceptability of each component. Interview content is guided by the multiple health outcomes framework (MHOF) and addresses major barriers (patient, provider, system) to surveillance and challenges (patient, provider, system) to the planned implementation of intervention components.

    Time frame: At time of interview

  2. Completion of surveillance colonoscopy (Aim 2)

    Will analyze rates during the study period using a generalized linear mixed model with a logit link that includes an indicator for study arm and random effects for clinic and primary care provider to account for the multilevel data structure.

    Time frame: At 3.5 years

  3. Implementation quality (Aim 3a)

    The Investigators will assess implementation quality and outcomes through stakeholder interviews (patients, providers, administrators) and chart reviews. The information gained will guide adaptations of the intervention for future use so that clinicians maximize effectiveness, feasibility, acceptability, sustainability, and impact. Findings will also determine the resources needed to successfully scale the intervention to different settings

    Time frame: Up to 3 years

  4. Cost effectiveness (Aim 3b)

    Will use standard cost-effectiveness techniques (including time discounting) to conduct an incremental cost-effectiveness analysis, measuring the Incremental Cost-Effectiveness Ratio of the natural language processing-based electronic health record intervention compared to usual care office outreach.

    Time frame: Up to 3 years

Secondary outcomes

  1. Time from high risk neoplasia (HRN) diagnosis to colonoscopy (Aim 2)

    Time frame: From HRN diagnosis to colonoscopy, up to 3 years

07

Study locations

1 of 1 sites recruiting
  • UCLA / Jonsson Comprehensive Cancer Center
    Los Angeles, California 90095, United States
    Recruiting
08

References and documents

Publications

  • May FP, McEwan JA, Tuan JJ, Crespi CM, Maehara CK, Yang JO, Uy A, Gupta S, Kang Y, Myint A, Naini BV, Elmore JG, Kadiyala S, Ong MK, Bui AAT, Hamilton AB, Chang LC, Gelvezon A, Hsu W, Bastani R. Increasing timely colonoscopy surveillance for patients with high-risk colorectal polyps: Protocol for a cluster randomized trial. Contemp Clin Trials. 2026 Jan;160:108147. doi: 10.1016/j.cct.2025.108147. Epub 2025 Nov 17. PubMed 41260460 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06376565
Lead sponsor
Jonsson Comprehensive Cancer Center
Collaborators
National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Apr 19, 2024
Start date
Nov 8, 2023
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Nov 14, 2025

Study contacts

Jenna Alarcon
Contact
JCAlarcon@mednet.ucla.edu
310-794-6197
Folasade P May
principal investigator · UCLA / Jonsson Comprehensive Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion